Tags

Type your tag names separated by a space and hit enter

Hormonal intrauterine devices.
Ann Med. 1993 Apr; 25(2):143-7.AM

Abstract

Intrauterine administration of progestogens from an IUD was introduced more than 15 years ago in order to improve the contraceptive efficacy and to reduce side-effects. A device releasing 20 micrograms levonorgestrel daily (Levonova) with a life span of at least 5 years is now available and has been subjected to an extensive study including 1821 women followed during 5 years. The safety and efficacy were evaluated in comparison to Cu-T IUDs. The pregnancy rate (Pearl index) was 0.09. During the first two cycles after insertion intermenstrual bleeding was common, otherwise the frequency of side-effects was low. The results seem to justify the conclusion that intrauterine administration of progestogens represents a further development of IUDs and hormonal contraception. Furthermore, these devices have proven to be effective in treatment of heavy menstrual blood losses. In many menorrhagic women, use of these IUDs can replace more invasive surgical methods such as hysterectomy or endometrial resection. Intrauterine administration of progestogens is also effective in opposing the proliferative effect of oestrogen on the endometrium in women on hormonal replacement therapy.

Links

Publisher Full Text

Authors+Show Affiliations

Rybo G
Department of Obstetrics and Gynecology, University of Göteborg, Ostra sjukhuset, Sweden.
Andersson K
No affiliation info available
Odlind V
No affiliation info available

MeSH

AdolescentAdultAmenorrheaEstrogen Replacement TherapyFemaleFollow-Up StudiesHumansIntrauterine Device ExpulsionIntrauterine Devices, MedicatedLevonorgestrelMenorrhagiaPelvic Inflammatory DiseasePregnancySwedenUterine Hemorrhage

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8489751

Citation

Rybo, G, et al. "Hormonal Intrauterine Devices." Annals of Medicine, vol. 25, no. 2, 1993, pp. 143-7.
Rybo G, Andersson K, Odlind V. Hormonal intrauterine devices. Ann Med. 1993;25(2):143-7.
Rybo, G., Andersson, K., & Odlind, V. (1993). Hormonal intrauterine devices. Annals of Medicine, 25(2), 143-7.
Rybo G, Andersson K, Odlind V. Hormonal Intrauterine Devices. Ann Med. 1993;25(2):143-7. PubMed PMID: 8489751.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Hormonal intrauterine devices. AU - Rybo,G, AU - Andersson,K, AU - Odlind,V, PY - 1993/4/1/pubmed PY - 1993/4/1/medline PY - 1993/4/1/entrez KW - Amenorrhea KW - Biology KW - Bleeding KW - Contraception KW - Contraception Continuation KW - Contraception Termination KW - Contraceptive Agents, Female--side effects KW - Contraceptive Agents, Progestin--side effects KW - Contraceptive Agents--side effects KW - Contraceptive Effectiveness KW - Contraceptive Methods KW - Contraceptive Mode Of Action KW - Contraceptive Usage KW - Demographic Factors KW - Denmark KW - Developed Countries KW - Diseases KW - Eastern Europe KW - Endometrial Effects KW - Endometrium KW - Europe KW - Family Planning KW - Fertility KW - Fertility Measurements KW - Finland KW - Genitalia KW - Genitalia, Female KW - Hungary KW - Infections KW - Iud KW - Iud, Hormone Releasing KW - Levonorgestrel--side effects KW - Menorrhagia KW - Menstruation Disorders KW - Northern Europe KW - Physiology KW - Population KW - Population Dynamics KW - Pregnancy Rate KW - Reversibility KW - Scandinavia KW - Signs And Symptoms KW - Sweden KW - Treatment KW - Urogenital System KW - Uterus SP - 143 EP - 7 JF - Annals of medicine JO - Ann Med VL - 25 IS - 2 N2 - Intrauterine administration of progestogens from an IUD was introduced more than 15 years ago in order to improve the contraceptive efficacy and to reduce side-effects. A device releasing 20 micrograms levonorgestrel daily (Levonova) with a life span of at least 5 years is now available and has been subjected to an extensive study including 1821 women followed during 5 years. The safety and efficacy were evaluated in comparison to Cu-T IUDs. The pregnancy rate (Pearl index) was 0.09. During the first two cycles after insertion intermenstrual bleeding was common, otherwise the frequency of side-effects was low. The results seem to justify the conclusion that intrauterine administration of progestogens represents a further development of IUDs and hormonal contraception. Furthermore, these devices have proven to be effective in treatment of heavy menstrual blood losses. In many menorrhagic women, use of these IUDs can replace more invasive surgical methods such as hysterectomy or endometrial resection. Intrauterine administration of progestogens is also effective in opposing the proliferative effect of oestrogen on the endometrium in women on hormonal replacement therapy. SN - 0785-3890 UR - https://www.unboundmedicine.com/medline/citation/8489751/Hormonal_intrauterine_devices_ L2 - https://www.tandfonline.com/doi/full/10.3109/07853899309164158 DB - PRIME DP - Unbound Medicine ER -